COVID-19: Inconsistencies in hydroxychloroquine data in the Lancet

Apple Podcasts or Listen Here

We are bringing you updates on COVID-19.  Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded May 30, 2020

On May 22, the Lancet published a study by Mehra et al that reported an analysis of an enormous international registry of 96,032 patients with COVID-19 that reported patients who received hydroxychloroquine, chloroquine, or these drugs combined with a macrolide had higher risk of mortality. This led to the WHO halting trials. At the same time, remdesivir’s popularity rose and the future for HCQ became bleak. However, some of the numbers just didn’t add up…and, it turns out, it is possible that the data was fabricated or some other serious wrongdoing occurred. More than 100 scientists from around the world have authored an open letter (Watson et al) regarding this concern.

There is one other published paper using the Surgical Outcomes Collaboration, unfortunately, this was the large NEJM study on ACE-I/ARBs in COVID-19, which suffers from similarly improbable data …see this thread

https://twitter.com/mikejohansenmd/status/1267132835871305731?s=20

*UPDATE 6/4/20* The authors have issued notices of retraction for both the hydroxychloroquine article as well as the ACE-I/ARB study , citing that they did not have access to the raw data. This is interesting because the NEJM letter is also signed by the author who is the CEO of Surgisphere, who curates the database used in the study, and the corresponding author reported in the original manuscript having full access to the data.

COVID-19: Remdesivir 5 vs 10 days

Apple Podcasts or Listen Here

We are bringing you updates on COVID-19.  Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded May 30, 2020

In the wake of the ACTT-1 trial on remdesivir (see post), enthusiasm has quickly grown. In this podcast we review Goldman et al, a Gilead funded study, looking at duration of treatment (not efficacy of remdesivir itself).

COVID-19: Clinical Exam Finding Accuracy

Apple Podcasts or Listen Here

We are bringing you updates on COVID-19.  Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded May 22 2020

We often want to know – does this patient have COVID-19 based on clinical features. These authors attempted to tackle this question

Peyrony et al. Ann Emerg Med. 2020; in Press
Likelihood ratios

Check out Brief19.com for daily research and policy briefings

COVID-19 – Literature Update

Apple Podcasts or Listen Here

We are bringing you near-daily updates on COVID-19. There is a firehose of information and most of us are too busy to read and digest it all. Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded May 15, 2020

Halfmann et al NEJM 2020
Holmes et al Lancet 2020
Knight et al – pre-print
See prior podcast on vertical transmission in pregnancy and pregnancy and breastfeeding in COVID
podcast on PIMSTSS
Toubiana et al pre-print
Verdoni et al Lancet 2020
Begley et al. Anaesthesia 2020
Meredith et al pre-print

COVID-19: Pediatric multisystem inflammatory syndrome temporally associated with COVID-19

Apple Podcasts or Listen Here

We are bringing you near-daily updates on COVID-19. There is a firehose of information and most of us are too busy to read and digest it all. Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded May 9, 2020

Royal College of Paediatrics and Child Health
Riphagen et al. Lancet 2020

COVID-19: Convalescent Plasma

Apple Podcasts or Listen Here

We are bringing you near-daily updates on COVID-19. There is a firehose of information and most of us are too busy to read and digest it all. Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded May 6, 2020

Rajendran et al (poor quality systematic review)
Shen et al
Zhang et al
Ye et al
Ahn et al
Duan et al
Biegel et al (influenza A RCT)

COVID-19: Antibody Testing

Apple Podcasts or Listen Here

We are bringing you near-daily updates on COVID-19. There is a firehose of information and most of us are too busy to read and digest it all. Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded May 2, 2020

Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;
IDSA COVID-19 antibody primer
IDSA COVID-19 antibody primer
Crook et al. MedRxiv pre-print